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Abstract
Fecal microbiota transplantation (FMT) is the process by which fecal suspension from a healthy

individual is transferred into the gastrointestinal tract of another individual in an attempt to cure
certain diseases. This transplantation process has been accredited as being a potential remedy for
a growing number of diseases that have been associated with gut microbial imbalances. Interest
in FMT has largely been driven by the science community’s increasing interest in the gut
microbiome and its role in potentially regulating a multitude of different functions and processes
within the human body. One disease that has been found to respond exceptionally well to FMT
treatments is 
Clostridium difficile
infection (CDI). However, while FMT has demonstrated high
cure rates for CDI, this transplantation process is no panacea. In fact, the results from FMT
treatments on other diseases, such as Inflammatory Bowel Disease (IBD), have not been as
impressive as CDI’s. This review will examine the existing literature surrounding FMT usage on
IBD and will propose a series of experiments and studies needed to truly test the safety and
efficacy of FMT for IBD patients. This review will also reference current literature documenting
FMT treatments for CDI as a comparative tool for investigating if this form of bacteriotherapy is
indeed a viable therapeutic option for treating IBD.
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Introduction.
Intestinal dysbiosis has been theorized as being a causative agent of illbeing for a variety
of different diseases. Fecal microbiota transplantation (FMT) offers promising therapeutic
options for microbiota restoration; it has found great success in the treatment of 
Clostridium
difficile 
infections (CDI), demonstrating high efficacy rates in the eradication of CDI and
CDIassociated symptoms (Rossen et al., 2015a). In addition to intestinal disorders, recent
studies have demonstrated relationships between alterations in the gut microbiome and disease
causation beyond intestinal disorders, such as with metabolic diseases, neuropsychic diseases,
and autoimmune diseases (Xu et al., 2015). Findings from such research have stirred an interest
in evaluating the potential therapeutic role FMT may have on certain extraintestinal disorders,
such as Inflammatory Bowel Disease (IBD). The etiology of IBD has long been speculated as
being a combination of genetic and environmental factors (Foster et al., 2016 & Ek et al., 2014).
Recently, intestinal dysbiosis and its association with IBD have fastly become accepted by much
of the research community, as shifts in one’s gut microbiome have been demonstrated to be an
influencing factor in IBD's multifactorial pathophysiology in multiple studies (Colman et al.,
2014). However, clinical trials that have attempted to test the efficacy of FMT for IBD patients
have been met with varying degrees of success; there have been many severe side effects that
have been associated with these FMT treatments as well (Rossen et al., 2015a). Because of these
findings, this review will attempt to investigate the efficacy of FMT for IBD and propose a series
of experiments aimed at testing the safety and effectiveness of FMT treatments for IBD. This
review will also utilize current literature on FMT treatments for CDI as a guide to finding
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existing FMT protocols and procedures as well as using it as a comparative tool for investigating
FMT as a therapeutic option for IBD patients.
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Clostridium difficile Infection.
Clostridium difficile 
infection (CDI) is a fastly growing problem in many industrialized
countries, causing problems that range from diarrhea to pseudomembranous colitis (an
inflammatory disease of the colon). CDI is caused by an opportunistic, gram positive bacterium,
called 
Clostridium difficile 
(
C. difficile
), that has spore forming and toxin producing capabilities
(Leffler et al., 2015). It has an oralfecal route of transmission amongst humans and is spread
when people come in contact with surfaces contaminated with feces containing 
C. difficile
bacteria and subsequently touch their mouths (Leffler et al., 2015). CDI symptoms usually
include: watery diarrhea (at least three bowel movements a day for two or more days), fever, loss
of appetite, nausea, abdominal pain or cramping, and dehydration (Sunenshine et al., 2006). CDI
is the leading causes of nosocomial (hospital acquired) diarrhea in Europe and North America,
and it is estimated that there are 500,000 cases of CDI that are diagnosed in the USA annually
(Rupnik et al., 2009). Recent outbreaks of CDI and the emergence of increasingly virulent strains
have been associated with CDI’s fastly growing morbidity and mortality rates, with there having
been a 23% annual increase of cases from 20002006 (Zilberberg et al., 2008) and a 20 fold
increase in mortality since its first diagnosis (Rupnik et al., 2009).
C. difficile
’s spore form allows it to survive even the toughest of circumstances as it
permits the bacterium to stay dormant until it reaches better conditions that allow for it to thrive
(Sunenshine et al., 2006). In humans, CDIs are transmitted when 
C. difficile
spores are ingested.
The spore form is resistant to the hostile gastric acid environment of the stomach and is then
passed into the intestines, where conditions are considerably more favorable for the bacterium to
grow (Sunenshine et al., 2006). The large intestine is where 
C. difficile
colonizes and induces 
C.

6

difficile
associated diseases (i.e. CDI) as a result of changes or disruptions to a host’s commensal
microflora (Sunenshine et al., 2006). 
C. difficile
germinates and produces toxins, which have
both enterotoxin (targets intestines) and cytotoxin properties (Heinlen et al, 2010). These toxins
can increase vascular permeability and hemorrhaging by opening up cellular tight junctions in
the intestines (Karmali et al., 2013). The toxins can also cause severe inflammation and mucosal
injury to the colon, potentially leading to pseudomembranous colitis, as a result of the toxins
producing tumor necrosis factoralpha and proinflammatory interleukins (Poxton et al., 2001). 
C.
difficile
toxins also cause damage to the GI tract, causing diarrhea in many CDI patients (Poxton
et al., 2001). The primary pathophysiological hypothesis for CDI and the cause for 
C. difficile
overgrowth is the bacteria’s ability to colonize the GI tract following a shift to a person’s normal
microflora; the current leading cause for such disruptions to the flora is the use of broad
spectrum antibiotics (Karmali et al., 2013).
As previously mentioned, 
C. difficile
is pathogenic due to its production of toxins; the
most predominant toxins produced are toxin a (TcdA) and toxin B (TcdB), both of whose
mechanisms of action include: being endocytosed by the cell, degrading the actin cytoskeleton,
and causing cell death (often in the colonic epithelium) (Heinlen et al,. 2010 & Poxton et al.,
2001). TcdA and TcdB are located on a pathogenicity locus of the 
C. difficile 
bacterium and have
similar primary structures. It is thought that the enzyme associated with cytotoxic activity for
both Tcd A and TcdB is located on the Nterminus of this pathogenicity locus (Poxton et al.,
2001). Binary toxin, 
C. difficile
transferase, is another toxin associated with CDI; it has been
attributed to causing hypervirulent strains of CDI by significantly increasing toxin a and toxin B
production (Barbut et al., 2005). An example of a CDI that produces the binary toxin is variant
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strain, Bi/naP1/027, which caused an epidemic of CDI between 20022005, accounts for
25%50% of all CDIs, and is currently the predominant strain of CDI in hospital isolates
(Ananthakrishnan, 2011). A distinguishing trait of Bi/naP1/027 is its resistance to
fluoroquinolones (a broad spectrum antibiotic drug) and the current widespread usage of
antibiotics may explain why there has been a selective pressure for the emergence of this
particular strain in recent years (Pépin et al., 2005). Other hypervirulent, variant strains of CDI
have also been on the rise since the early 2000s (i.e. ribotype 078); many of these strains have
been associated with increased symptom severities and inflated mortality rates, making the
eradication of CDIs an extremely important area of current research (Goorhuis et al., 2008).
In addition to escalating morbidity and mortality rates, many hypervirulent strains of
CDIs have high recurrence rates. Patients with CDI are usually treated with rounds of the
following antibiotics: metronidazole (for mild to moderate cases), vancomycin (for severe cases),
and fidaxomicin (for severe cases) (Gerding et al., 2016). While these antibiotics eliminate a
majority of CDI symptoms in patients, recurrences after treatments with antibiotics for an initial
infection range from 15%35%, within an 8 week timeframe, and recurrence rates have been
found to increase to 77% after more than one CDI recurrence (Gerding et al., 2016). Because of
the high failure rates of standard therapy regimens, alternative methods for treating CDIs have
been highly sought after.
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Inflammatory Bowel Disease.
Inflammatory Bowel Disease (IBD) is a class of autoimmune diseases that affect millions
of people worldwide; it causes inflammation of the GI tract that leads to symptoms of diarrhea
and abdominal pain in patients. IBD is primarily comprised of two major disorders: Crohn’s
Disease (CD) and Ulcerative Colitis (UC); chronic uncontrolled inflammation of the intestinal
mucosa in the GI tract (esophagus, stomach, small intestine, large intestine, etc) is the hallmark
of this class of diseases (Papadakis et al., 2000). In the United States, it is estimated that 1
million people currently suffer from IBD, and there are about 30,000 new cases that are
diagnosed each year; the distribution of which is primarily divided amongst CD and UC
(Hanauer, 2006). While the diagnosis of IBD can be made at any age, there seems to be a
bimodal age distribution for these diseases with the first peak occurring around age 30 and the
second peak occurring between ages 4070 (Ali, 2015). Previous studies have also shown that an
early onset of CD (<16 years old) may cause more severe forms of Crohn's when compared to
adult onset CD (Ali, 2015).
While similar in many regards, CD and UC have many differences as well. For example,
the location of CD inflammation is usually found in the distal ileum and the colon (although
inflammation can occur in an part of the GI tract from the mouth to the anus), while UC
inflammation occurs exclusively in the colon (large bowel) (Laass el al., 2014). The spread of
inflammation in CD tends to be discontinuous and patchy with skip lesions; the spread of
inflammation in UC is usually continuous from the rectum to the colon (Laass el al., 2014). In
CD, all layers of the bowel wall are affected by inflammation (transmural inflammation), but in
UC, only the mucosa and submucosa layers are affected (superficial inflammation) (Laass el al.,
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2014). Other diagnostic features that typify CD are the presence of fissures (tears or cracks
along the anus) and fistulas (sores or ulcers in the intestinal tract) (Laass el al., 2014).
Furthermore, UC seems to affect males more than females; CD is marginally more frequently
seen in females. However, both diseases seem to be more prevalent within urban populations and
tend to be diseases associated with higher socioeconomic groups (WiercinskaDrapalo et al.,
2005).
The distribution of IBD amongst racial and ethnic groups is highly fluctuating. In the
past, it was speculated that IBD occurred more frequently in white populations than in ethnic or
racial minority groups (Hanauer, 2006). However, this gap has been fastly closing as studies
have demonstrated marked increases in IBD diagnoses in African American populations and
second generation south Asian populations that have immigrated to developed countries (such as
the US and the UK), highlighting the importance of environmental factors in the development of
these diseases (Foster et al., 2016). Adding on to the idea that environmental factors increase the
prevalence of IBD, it is highly speculated that “Westernization” (i.e. consumption of processed
foods and industrialization) is an influencing factor in the recent rise of IBD diagnoses as well,
as populations that were previously considered low risk for IBD are now experiencing much
higher rates of IBD incidence (Ponder et al., 2013). For example, IBD is most prevalent in
developed countries, such as the US and Scandinavia (Hanauer, 2006). However, over the past
few decades, IBD has been steadily increasing in Asian pacific regions, correlating to the
industrialization and “Westernization” of these areas (Ng et al., 2013). As developing countries
experience a rise in IBD diagnoses, a noticeable trend that appears is that UC tends to appear
first followed by rising rates of CD (Bernstein et al., 2008). Other environmental factors that
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seem to influence IBD prevalence include: stress, smoking, diet, breast feeding, and exposures to
medication (Ponder et al., 2013).
In addition to environmental factors, the etiology of IBD is believed to be affected by
genetic factors as well. Over the years, more than 160 susceptibility loci/genes have been
associated with IBD; these genes tend to encode for various proteins that have a role in
influencing and potentially downregulating: barrier functions, the immune system (both innate
and adaptive), and microbial defense mechanisms (Cho et al., 2011). The focus of gene
discovery for CD and UC have been largely distinctive, with there having been more attention
paid to issues of autophagy, innate immunity, and abnormal bacterial processes for CD and
barrier function for UC (Ponder et al., 2013). Through multiple twin studies and data compilation
studies done on IBD, it has been demonstrated that there is usually a greater incidence of IBD
within families (aka family aggregation/familial IBD); 523% of patients have first degree
relatives who are also affected by IBD (Ek et al., 2014). In a twin study done on IBD, it was
found that monozygotic twin pairs had higher concordances for CD than dizygotic twin pairs did,
highlighting the effects of genetics in this disease pathology (Ek et al., 2014). Studies have also
shown that UC patients are affected by genetic predispositions as well, although the results have
not been as pronounced as those that have been found for CD (Orholm et al., 2000). It is
hypothesized that the interplay between genetic predisposition and environmental exposures
(which in turn can affect immune system functioning) are all influencing factors in IBD
pathogenesis.
A theory on the etiology of IBD that demonstrates the intersection of: genetics, the
environment, and host immune system functioning, is the hygiene hypothesis. The hygiene
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hypothesis proposes that clean environments (i.e. germ free) and declining incidences of
infectious diseases, as is the case in much of the Western world and in many developing
countries, are the causes of the sudden rises in autoimmune diseases and allergy disorders seen in
the past couple of decades (Azad et al., 2013). In support of the hygiene hypothesis, previous
studies have shown that reduced microbial diversity (i.e. as a result of antibiotic usage or being
raised with limited microbial exposure) in infancy has been linked to the development of allergy
diseases later on in life (Azad et al., 2013). However, studies still show conflicting results in
showing whether it is the diversity of the microbiota or the gut microbial composition itself (i.e.
specific species) that has more weight in determining the evasion of disease (Azad et al., 2013).
A popular mechanism that seems to support the hygiene hypothesis is the Th1/Th2
model (WillsKarp et al., 2001). Th1 cells of the immune system produce interferons and
tumornecrosis factors, which are important signalling cytokines for producing macrophage,
phagocytosis, and immunity responses (WillsKarp et al., 2001). Th2 cells, on the other hand,
produce a different set of cytokines (i.e. interleukins), whose primary functions include
inhibiting the activation of macrophages and producing antibodies (IgE) (WillsKarp et al.,
2001). Studies have shown that imbalances in Th1 and Th2 levels (i.e. compositions skewed
toward Th2) tend to confer disease (i.e. allergies) (Prescott et al., 1998). In light of these
findings, much research has gone into investigating if Th1 stimulation (i.e. through intentional
microbial introductions) during early infancy has an effect on providing disease immunity later
on in life, and has found varying degrees of success (Prescott et al., 1998). Therefore, more work
still needs to be done on microbial exposures, its effects on regulatory Tcells, and its effects on
maintaining a homeostatic balance between functions of: inflammation, antiinflammation, and
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immune tolerance, as disruptions in this balance tend to confer disease (i.e. autoimmune
diseases).
Microbial exposure and its association with immunoregulatory defects seem to play a
role in the pathogenesis of IBD as well (Hanauer, 2006). The IBD hygiene hypothesis states that
children raised in an environment that is overly hygienic will experience negative impacts on
their immune development, which causes them to be more susceptible to autoimmune diseases
like IBD later in life (Weinstock et al., 2009). Because researchers have previously known that
areas associated with higher socioeconomic status tend to have higher incidences of IBD, it was
long speculated that something about the environment of developed countries conferred higher
susceptibility to IBD and other autoimmune diseases. A theory stemming from the hygiene
hypothesis, which may explain why IBD rates are so much higher in developed countries, is that
there is a lack of helminth (large parasitic worms) exposure in developed countries due to
sanitation efforts (Zhang et al., 2014). To live within their hosts, helminths have been shown to
be able to activate cells of both the innate and adaptive immune system, suppressing
inflammation in order to avoid being rejected by its host (Elliott et al., 2012). Helminth
colonization has been shown to suppress intestinal inflammation as well, which is the primary
pathology of IBD (Elliott et al., 2012).
In addition to increased efforts of becoming more hygienic in developed countries, which
prevent the colonization of organisms that potentially provide protective advantages against
autoimmune disorders such as IBD, many studies have hypothesized that a disruption in a
person’s own commensal microflora has a role in IBD pathogenesis as well (Colman et al.,
2014). Microbiota colonization of the human gut starts from birth (in which the mother’s own
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microbiota provides the neonate with its first microbial inoculum); the composition of this
microbial community changes as a baby is introduced to various changes in its life (i.e. diet,
early microbial exposures, medications, etc) (Palmer et al., 2007). An infant’s microflora
increases in diversity and richness until around early childhood (typically 35 years old), when
their microbiota starts to stabilize and resemble adultlike microbial compositions; shifts in this
established microbial ecosystem (i.e. via use of antibiotics, surgery, etc) tends to confer disease
(Rodríguez et al., 2015).
In recent years, many studies have shown that gut microbiota dysbiosis has an negative
effect on the development of proper immune responses and that producing an appropriate
immune response is highly dependent on the colonization of microbiota in the GI tract
(Nagalingam et al., 2012). For example, a study done on germ free rabbits demonstrated that the
sterilely derived rabbits acquired gut microfloras that were completely different than that of the
conventionally raised rabbits; it was concluded that certain microbial species were needed for
proper antibody repertoire diversification (although the exact species of influence remain to be
elucidated) (Lanning et al., 2000). Another study that used gnotobiotic mice (germ free mice or
mice whose microbial species are completely accounted for), found that these mice failed to
produce normal immune responses (Rask et al., 2005). Further evidence that demonstrates that
the gut microbiome has an effect on immune response regulation and modulation are
experiments that have shown that germ free mice have fewer: Peyer’s patches (which are crucial
for the surveillance and eradication of pathogens in the GI tract), a thinner lamina propria (which
is home to numerous immune cells), mature lymphoid follicles, Tcells, and Paneth cells (which
secrete antimicrobial molecules) (Round et al., 2009). Other experiments have also shown that
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certain bacterial species that inhabit the gut can produce defensins (i.e.
Bacteriodetes
thetaiotaomicron
) and can activate the host immune system in order to improve their own fitness
(i.e. 
Salmonella enterica
), further demonstrating the role the microbiome has on
immunoregulation (Stappenbeck et al., 2002 & Winter, et al., 2010). As shown from these
studies, a healthy gut microbiome is tightly linked to proper regulation of host immune
responses; a dysbiosis in this microflora can lead to defects in immunoregulatory pathways that
lead to diseases.
In IBD, there has been increasing support made for the hypothesis that the
gastrointestinal microbiomehost immune response axis has a role in IBD pathogenesis. In fact,
there has been research indicating that a person’s commensal gut microflora has a role in
triggering, maintaining, and establishing IBD phenotype (Sartor, 2008). For example in CD
patients with inflammation in the ileum, a study found that two genera of bacteria were
decreased: 
Faecalibacerium
and 
Roseburia
(Sartor, 2010). Research has shown that these
genera tend to produce shortchain fatty acids, which normally provide protection to the
intestines, illustrating how microbiota dysbiosis can potentially be a factor in determining IBD
phenotypes (Sartor, 2010). Research has also shown that CD patients, in a couple of studies,
were found to have lower levels of 
Faecalibacterium prausnitzii
, which has previously been
linked to having antiinflammatory capabilities, demonstrating how shifts in one’s healthy gut
microbiota might lead to the onset of intestinal inflammation associated with IBD (
Sokol et al.,
2008
).
In a review article outlining the role of gut microbiota in IBD pathogenesis, it was stated

that there are four broad mechanisms that help to elucidate the relationship between IBD (and its
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pathology of intestinal inflammation) and one’s commensal gut microflora: (1) there is a
dysbiosis of the commensal enteric microflora (i.e. in several studies, IBD patients showed
depletion of 
Bacteroidetes 
and 
Firmicutes
groups and an abundance of 
Actinobacteria 
and
Proteobacteria
groups), (2) there are alterations in the gut microbiome, either pathogenically or
functionally, that lead to inflammation of the intestines (i.e. alterations that lead to increased
mucosal adherence of a foreign microbe, which causes an increased immune response leading to
inflammation), (3) there are host genetic defects that lead to increased microbial antigenic
exposure (i.e. mutations that lead to a more permeable epithelial layer in the intestines and a
subsequent increased immune response), (4) there is impaired host immunoregulation (Sartor et
al., 2012). All of these proposed mechanistic pathways cause an upregulation of Tcells and
innate immune cells (i.e. natural killer cells, neutrophils, dendritic cells, etc) in the intestinal
mucosa due to an increased exposure to bacterial antigens (Sartor et al., 2012). This increased
stimulation of the immune system can ultimately cause chronic inflammation of the intestines,
leading many to speculate that commensal microbial dysbiosis is indeed a contributing factor to
IBD pathogenesis.
Currently, there is no cure for these autoimmune diseases and there are only treatment
options to help control the disease symptoms such as: steroids (corticosteroids),
antiinflammatory drugs, antibiotics (for skin lesions and bacterial infections), and surgery
(Cammarota et al., 2015). However, most of these conventional therapies have negative side
effects as well. For example, while many IBD patients who choose to undergo surgical
procedures, to cut out inflamed areas, often find themselves symptom free for the first couple of
years postsurgery, their IBD symptoms almost always seem to return (Cammarota et al., 2015).
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Potential dangers associated with using steroid treatments are issues of patients becoming steroid
dependent, as well as the risk of developing a steroidrefractory disease (in which steroids no
longer prove to be effective for disease treatment) (Cohen et al., 2016). Current studies have
proposed a couple of new therapeutics, and they stem from the current hypothesis that gut
microbial dysbiosis has a role in IBD pathogenesis. These therapy options include: probiotics
(which are live microorganisms that are thought to confer health benefits when administered in
small amounts) and prebiotics (which are fiber compounds believed to promote the growth of
“good bacteria”) (Cammarota et al., 2015). While a few studies have shown that some probiotics
demonstrate higher rates of IBD symptom resolution when compared to their placebo drug
counterparts (i.e. 
VSL#3
, a probiotic cocktail), there are risks that come with this therapy as well
(
Cammarota et al., 2015
). For example, the usage of probiotics as a treatment option for IBD
patients has been recorded to cause sepsis in a handful of cases (
Cohen et al., 2016
). There is
also very limited data showing the efficacy of probiotics on severely immunocompromised IBD
patients, demonstrating the need for more clinical trials that test the effectiveness of probiotic
usage on patients with IBD. In addition to probiotics, another emerging form of therapy for IBD
treatment is fecal microbiota transplantation, which 
looks to be a promising therapeutic option
for microbial restoration.

17

Fecal Microbiota Transplantation.
FMT is argued to have been implemented for some 1,700 years. The earliest practice of
it is said to have taken place during 4th century China when Ge Hong, a traditional Chinese
medicine doctor, administered human fecal matter orally to patients with food poisoning and
severe diarrhea, and found great success with his new treatment regime (Zhang et al., 2012). So
while FMT is not a novel concept in and of itself, the first medically documented case of FMT
usage in modern times was not until 1958 when it was used to treat pseudomembranous colitis in
a four person case study (Eiseman et al., 1958). The first usage of FMT as a means for treating
CDI was in 1983 by means of enema (Schwan et al., 1983).
FMT is the process by which fecal suspension from a healthy individual is transferred
into the GI tract of another individual in an attempt to cure certain diseases. The concept behind
this treatment is that each living organism has a certain gut microbiota composition that makes
up its microbiome (all microbial genes). Yet, even the microbiomes of healthy individuals vary
greatlythe diversity of which still remains unexplained, although diets, early microbial
exposure, and environmental factors are some of the many influences of microflora changes
(Consortium, 2012). Although there is no specific microbiota composition across healthy
individuals that confers wellbeing, studies have shown that certain taxa are usually more
associated with a “healthy” microbiome while certain other bacterial species tend to be linked to
disease; these revelations have been the basis for the fastly growing prebiotic and probiotic
industry.
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The gut microbiome is responsible for many different critical functions, including:
immune functions, digestion, and colonization resistance (Schubert et al., 2014). Colonization
resistance is the ability to prohibit and restrict the colonization and growth of pathogenic species.
The idea of colonization resistance is one of the key concepts behind why FMT has found such
great success with CDIs, as CDIs are thought to be caused by a significant decrease in an
individual’s healthy microbiota species, allowing for the colonization of pathogenic bacterial
species that cause CDI (Schubert et al., 2014).
Because FMT has shown promising results as a treatment for CDIs, FMT has also been
hypothesized as being effective for a variety of other diseases as well, such as: intestinal
disorders (i.e. Inflammatory Bowel Disease, Irritable Bowel Disease, and metabolic diseases),
neuropsychiatric disorders, autoimmune diseases, and allergy disorders (Malnick et al., 2015 &
Xu et al., 2015). After CDIs, IBD has been one of the most highly studied class of diseases in the
FMT treatment realm. However, FMT usage on IBD is in much more of a preliminary stage of
testing than with CDIs, and scientists are still currently running many trial studies and
experiments in an attempt to better elucidate how FMT can best be used to treat patients with
IBD (Malnick et al., 2015). Results from many of these clinical trials, testing the efficacy of
FMT on IBD, have been found to be substandard to those of CDI, both in terms of effectiveness
and its safety profile, demonstrating a need for more research to reveal if FMT is truly a safe
option for IBD patients.
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Results.
Clostridium difficile Infection:

Methods of Administration
There is no singularly successful way of FMT administration. FMT is usually administered to
either the upper GI tract (i.e. via Nasogastric tubes or NGT, duodenal tube, endoscopy) or the
lower GI tract (i.e. via colonoscopy, retention enemas) (Dodin et al., 2014). In 2011,
approximately 23% of FMT procedures were administered using a NGT or gastroscopy and
demonstrated cure rates of 76% (Rohlke et al., 2012). In order to avoid aspiration, however,
delivery of fecal suspension to the upper GI tract requires administration of smaller volumes of
suspension (Dodin et al., 2014). A metaanalysis study (consisting of 182 participants from 12
published studies) compared and analyzed the success rates of using FMT via colonoscopy or
nasogastric tube. Although it was found that there were higher cure rates with the colonoscopy
group, ultimately there was no significant difference in treatment efficacy (between colonoscopic
and NGT FMT) (Postigo et al., 2012). Recurrence of CDI after FMT treatment, between both
methods of delivery, was also found to be statistically insignificant in this study (colonoscopy
group: 5.4% and NGT group: 5.9%) (Postigo et al., 2012). Another review paper found that FMT
administration through a gastroscope or NGT showed the lowest resolution rates (Gough et al.,
2011). Therefore, in general, colonoscopy is considered to be the first line approach for FMT
delivery in adults and upper GI tract FMT is used more for pediatric patients and patients with
severe comorbidities, but methods of administration still largely remain up to a physician or
researcher’s discretion (Dodin et al., 2014).
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Fecal Solution Preparation
The systematic analysis of Gough et al. demonstrated that using water as a diluent shows higher
resolution rates than using saline solutions (Gough et al., 2011). However, the relapse rate is two
times greater for solutions prepared with water than with saline (Gough et al., 2011). Other
diluents such as: milk, saline with psyllium, and yogurt also appear to demonstrate great efficacy
(Gough et al., 2011). Larger volume suspensions seem to be more effective than smaller volume
suspensions, with a study finding a 97% resolution rate for suspensions greater than 500 mL and
only a 80% resolution rate for 200 mL suspensions (Rohlke et al., 2012). Some studies have also
found that relapse rates are four times higher in solutions that use less than 50 grams of stool
(Rohlke et al., 2012). Other studies have shown that there is not a significant difference on
resolution rates using either fresh or frozen stool samples in FMT treatments (Hamilton et al.,
2012). Another clinical trial has also proposed the efficacy of using oral, capsulized, frozen fecal
matter, asserting that their orally prepared FMT pills had resolution rates of 90% (Youngster et
al., 2014).

Bowel Lavage Procedure
Polyethylene glycol electrolyte lavage was a standard protocol in many of the reviewed studies
that used colonoscopic FMT procedures, as the lavage is presumed to flush out residual traces of
feces, antibiotics, and CD (bacteria, spores, and toxins) before FMT administration (Rohlke et
al., 2012). However, systematic analysis reveals that patients who receive both bowel lavage and
an antibiotic before FMT tend to show the highest rates of relapse (Gough et al., 2011).
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Patients
Inclusion of patients into clinical trials greatly varied from trial to trial. Studies often included
patients who who had at least a couple (i.e. 2 or 3) documented recurrences of CDI despite
standard antibiotic therapy (Hamilton et al., 2012). Multiple studies excluded patients who were
under the age of 18 and/or had life expectancies of less than one year (Hamilton et al., 2012).
Other patient participation exclusions included patients who were pregnant, severely
immunocompromised (i.e. patients on chemotherapy), or taking other antibiotics aside from the
standard treatments for CDI (Bowman et al., 2015). Patients were usually also maintained on
antibiotics (i.e. a full dose of vancomycin) until a few (i.e. 2) days before the FMT procedure
was to be done (Hamilton et al., 2012).

Donors
A variety of donors can be used in the FMT process (i.e. family, friends, partners, relatives, or
unrelated healthy subjects) (Rossen et al., 2015a). In the past, descriptions of donors were not
well documented as they were only described as being “healthy donors” (Malnick et al., 2015).
Up until 2011, partners or family members were most frequently used as donors (Malnick et al.,
2015). Nowadays, donors are screened intensively before they are allowed to make fecal
donations. Donor screenings can include: questionnaires addressing risk factors for potentially
transmissible diseases, a fecal test, tests for parasites (including
Blastocystis hominis
and
Dientamoeba fragilis
), tests for CD and enteropathogenic bacteria, serology tests, antibody tests
(for HIV, human Tcell lymphotropic virus types 1 and 2, hepatitis A, B, and C,
Cytomegalovirus, EpsteinBarr virus), and tests for certain microbes (i.e.
Treponema pallidum,
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Strongyloides stercoralis, 
and
Entamoeba histolytica
) (Rossen et al., 2015a). At times, donors
were excluded from participation in certain studies if they: had gastrointestinal comorbidities,
used antibiotics in the months prior to donation, and showed presence of features resembling
metabolic syndrome, autoimmunity, or allergic diseases (Hamilton et al., 2012). It was
previously believed that fecal donations from related donors demonstrated higher rates of
resolution than with unrelated donors. (Gough et al., 2011). However, more recent clinical trials
make the argument that there is no such effect on resolution rates (Youngster et al., 2014).
Gough et al’s metaanalysis also claimed that male donors showed 86% resolution rates with a
0% relapse rate, while female donors showed 100% resolution rates but had an 8% relapse rate
(Gough et al., 2011).

Efficacy
In 2011, based on 27 case series, it was determined that FMT had a 92% efficacy rate, where
89% of patients experienced resolution after a single treatment; 4% of patients experienced
relapses (Gough et al., 2011). Based on a systematic review on FMT published in 2015, which
included 33 cases series published on CDI, the efficacy of FMT (defined as “resolution of
diarrhea”) ranged from 87.8% to 90.0% in repeated FMTs (Rossen et al., 2015a). A study
showed that severe and complicated cases of CDI, hospitalized patients, immunocompromised
patients, patients with more than three episodes of CDI, and patients with IBD comorbidities
demonstrated efficacies of more than 80% (Rossen et al., 2015a).
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Table 1
. Studies on fecal microbiota transplantation in 
C. difficile 
infection with an emphasis on
the potential side effects of these treatments.

Author

Year

Participants

Delivery
Method

Results of FMT

Side Effects

Follow
Up Period

Other Notes

Alang et al

2015

1

NM

CDI resolved

Obesity

NM

Daughter was stool
donor; daughter was
also gaining weight

Lee et al

2016

232

Enema

Clinical
resolution:
83.5% for
frozen and
85.1% for the
fresh

Mild to moderate:
transient diarrhea,
abdominal
cramping, nausea,
constipation, etc

13 weeks

First randomized
controlled trial to show
that frozen FMT is
noninferior to fresh
FMT in terms of
clinical efficacy

Hourigan
et al

2015

8

Colonoscopy

FMT provided
clinical
improvement in
children with
and without
Inflammatory
Bowel Disease
(IBD)

Mild prolonged
diarrhea for 6
months postFMT,
fecal urgency,
intermittent fecal
incontinence in 1
patient (without
IBD)

6 months

Patients were all
children; 5 patients had
IBD comorbidities

**NM= not mentioned
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Inflammatory Bowel Disease:

Methods of Administration and frequency:
Like with CDI, there is currently no standardized procedure of FMT administration for IBD
patients. However, the majority of FMT for IBD patients seem to be administered via the lower
GI tract (Anderson et al., 2012). Of the patients that had FMT delivery via the lower GI tract
(which typically includes the anus, rectum, colon, and cecum), most the patients received
enemas, followed by colonoscopic procedures (Colman et al., 2014). When FMT is administered
via the upper GI tract (which typically includes the esophagus, stomach, and duodenum), the
most popular route of administration seems to be through nasogastric/nasojejunal (NJ)
procedures, followed by gastroscopic installation (Colman et al., 2014). A previous study has
also been documented using a combination of upper and lower GI tract FMT administration
(nasojejunal tube and enema) (Angelberger et al., 2012). However, this study found little
efficacy in its FMT treatments after a follow up period of 12 weeks (Angelberger et al., 2012).
Another study also found that one of its patients developed aspiration pneumonia as a result of
NJ tube administration; the route of administration was changed to a rectal tube afterwards for
safety reasons (Vermeire et al., 2015). A systematic review published in 2014 revealed that 41%
of patients received FMT more than once; one study reported that a patient received as many as
70 FMTs (Colman et al., 2014). Another review found that only a small majority of IBD patients
received only a single infusion, and all of those patients were also being treated for comorbid
cases of CDI (Anderson et al., 2012).
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Fecal Solution Preparation:
Fecal matter for IBD patients are delivered both as fresh stool samples and frozen stool samples;
the majority of patients (data collected from five different studies) that seemed to achieve clinical
remission received fresh stool samples (Colman et al., 2014). Many studies failed to report how
their fecal solutions were prepared. When reported, fresh fecal sample collection took place from
10 mins to 6 hours before FMT administration (Anderson et al., 2012). The amount of stool used
was generally between 200300 grams, and the stool samples were usually suspended in 200300
mL of normal saline, but there are fluctuations in these numbers across different studies
(Anderson et al., 2012). Recently, in Nanjing, China, an automatic system has been developed to
normalize the fecal purification process; the machine is called the GenFMTer (Cui et al., 2015a).
The GenFMTer can cut the stool preparation time, from collecting the feces to delivery of the
final product, from 60 minutes (when prepared by operators) to less than 15 minutes, and the
GenFMTer is said to better preserve the microbiota isolated from stool samples (Cui et al.,
2015a).

Bowel Lavage Procedure
It was not always noted whether or not bowel lavage procedures were performed on patients
prior to FMT administration. When noted, polyethylene glycol was usually the solution delivered
to patients in these procedures (i.e. via NJ tubes) (Grehan et al., 2010 & Angelberger et al.,
2013). However, bowel lavage procedures have also been omitted from the FMT preparation
steps as well (Kump et al., 2013). The efficacy of bowel lavage procedures on IBD patients still
remains to be elucidated. Some studies required that their patients undergo “full bowel
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preparations”, but whether that refers to bowel lavage procedures or not remains unknown
(Vaughn et al., 2014).

Patients
Each study had its only set of inclusion criteria that allowed for patients to partake in certain
clinical trials. Studies tended to include both pediatric and adult patient demographics, with a
few studies focusing exclusively on younger patients (Colman et al., 2014). Studies tended to
include patients with active IBD flareup symptoms (i.e. moderate or severely active UC),
usually confirmed via endoscopy, colonoscopy, or histology procedures, and patients with
chronic active therapy–refractory IBD (patients who no longer respond to standard medical
therapies) (Kump et al., 2013 & Angelberger et al., 2013). However, some studies only allowed
patients with refractory IBD to partake in their clinical trials (Vermeire et al., 2015 & Kump et
al., 2013). Other studies purposefully excluded patients with refractory IBD (Vaughn et al.,
2014). Additional exclusion criteria from studies included: smokers, patients on antibiotics,
steroids, and/or probiotics, patients who had severe comorbidities (i.e. cardiac, renal, or hepatic
comorbidities), patients with short bowels, patients who were pregnant, patients who were under
16, etc (Vaughn et al., 2014, Vermeire et al., 2015, Kump et al., 2013). One study required that
its patients receive antibiotics (metronidazole, 500 mg twice a day) during the week prior to
being admitted into the hospital for the FMT procedure (Angelberger et al., 2013). Some studies
did not give their patients antibiotics prior to the FMT treatments (Vaughn et al., 2014).
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Donors
Not all studies included descriptions of their donor screening processes and/or donor selection
processes; others simply described their donors as being “healthy donors” (Colman et al., 2014).
In many studies, donors were described as being either being anonymous donors or related
donors (i.e. parents, siblings, children, partners) (Colman et al., 2014). However, several studies
prohibited IBD patients from receiving stool samples from donors who were related to them
and/or living in the same household as them (Kump et al., 2013). Some common donor criteria
included a negative history: for intestinal diseases (and/or GI infections), autoimmune diseases,
common viruses (i.e. hepatitis A, B, C, HIV, 
EpsteinBarr, Herpes simplex
, etc),
enteropathogens (i.e. 
Salmonella spp., Shigella spp., Aeromonas spp., 
etc), etc (Kump et al.,
2013 & Angelberger et al., 2013). Some recent studies have also been collecting donor stool
samples for further microbiota analyses (i.e. via RNA pyrosequencing techniques) (Cui et al.,
2015b). One study required that their donors undergo a lavage procedure prior to having their
stool samples collected (Kump et al., 2013).

Efficacy
Overall, remission rates for IBD patients using FMT treatments vary greatly; while some studies
found resolution rates of 68% other studies found resolution rates of 0% (Rossen et al., 2015a).
In a systematic review written in 2014 (which included 119 patients), the clinical remission rate
was said to be 45% after follow up (Colman et al., 2014). However, the length of the follow up
periods varied greatly and the average length of the follow up periods was only 1.5 months
(Colman et al., 2014). The systematic review also described that 6% of patients’ health
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conditions deteriorated post FMT treatment, but two of those patients seemed to have recovered
by week 8 after their treatments (Colman et al., 2014). Another review reports that resolution
rates fall to 36.2% when studies were excluded due to publication biases (Kelly et al., 2015). In a
few pediatric studies, the remission rates were found to be around 6065%, but were revealed to
have short follow up periods post FMT (Colman et al., 2014). In a randomized control trial of
FMT in IBD, remission was achieved in 24% of patients who received FMT and 5% of patients
who received a placebo (Moayyedi et al., 2015). In general, studies that used methods of clinical
scoring of disease activity (i.e. CD Activity Index, Mayo Index) and randomized control trials
tended to show lower efficacy rates for FMT in IBD (Ianiro et al., 2014).
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Table 2
. Studies on fecal microbiota transplantation in Inflammatory Bowel Disease with an
emphasis on the potential side effects of these treatments.

Author

Year

Participants

Delivery
Method

Results of FMT

Side Effects

Follow
Up
Period

Other Notes

Quera et al

2014

1

Colonoscopy

Asymptomatic
for CDI

High fever,
Bacteremia
(treated with
aztreonam)

5
months

CDI comorbidity;
patient had previous
cases of bacteremia
preFMT

De Leon
et al

2013

1

Colonoscopy

Resolution of
CDI symptoms;
UC remission

Transient flare
up of
“quiescent” UC,
abdominal
cramping,
tenesmus, etc

2 weeks

CDI comorbidity,
Wife was stool donor

Angelberger
et al

2013

5

NJ + Enema

Positive clinical
response for 1
patient

Temporary
increase of
Creactive
protein, fever,
vomiting, etc

12
weeks

Patients had severely
active UC

Cui et al

2015(b)

30

Endoscopy

76.7% clinical
improvement

Increased
diarrhea, fever

15
months

Mesalazine (3.0 g)
was given daily for 3
months post FMT for
its antiinflammatory
effects

Kunde et al

2013

10

Enema

67% maintained
clinical response
at 1 month; 33 %
maintained
clinical
remission after 1
week

Mild: cramping,
fullness,
flatulence,
bloating,
diarrhea, blood
in stool

1
month

Participants’ ages:
721 years old

Moderate: fever
Adverse:
selflimiting

**NM=not mentioned
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Discussion.
Fecal microbiota transplantation has been advertised as a promising microbial restoration
panacea that has the capabilities to treat a broad spectrum of diseases and disorders ranging from
gastrointestinal diseases (i.e. CDI and IBD) to a variety of nonGI diseases (i.e. obesity,
Parkinson’s, autism, multiple sclerosis, etc) (
Aroniadis et al., 2013
). While studies have
hypothesized that these transplantation treatments have the capability to elicit positive results in
curing and resolving the symptoms of many of the aforementioned ailments, there is a lack of
literature and properly conducted clinical trials that support the efficacy of FMT usage on many
of these diseases (
Ianiro et al., 2014
). The only disorder that seems to exhibit convincing success
rates with FMT treatments is CDI, where cure rates tend to exceed 90% in many clinical trials
that have tested the efficacy of FMT in CDI (
Aroniadis et al., 2013
). Because of its high cure
rates and the relatively limited amount of adverse side effects it causes, FMT is now considered
an effective therapy for treating recurrent 
C. difficile
infections (
Rossen et al., 2015a
).
However, while FMT has generally been accepted as a relatively safe and e
ffective
therapy for treating CDI, clinical trials that have tried to duplicate the therapeutic designs of
FMT for Inflammatory Bowel Disease have found inferior results to those found in CDI in terms
of cure rates, symptom resolution rates, and safety profiles (Ianiro et al., 2014). Existing
literature shows that the efficacy of FMT in IBD fluctuates greatly, and that the average clinical
remission rate is said to be approximately 45% (Colman et al., 2014). These rates tend to be even
lower when any sort of clinical measure of disease activity or objective score is used; the current
cure rate may also potentially be further curtailed if studies had longer follow up periods
(Colman et al., 2014 & Ianiro et al., 2014). In addition to the relatively low efficacy of FMT in
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IBD, these transplantation treatments also tend to demonstrate a lower safety profile for IBD
patients than for CDI patients; it has been noted that a worsening of disease is a potential adverse
side effect associated with FMT in IBD (De Leon et al., 2013). Because of this, great
consideration must be taken into account when determining whether these transplantations are
truly safe options for treating Inflammatory Bowel Disease.
Because of these concerns, this review will propose a series of goals and studies aimed at
testing the safety and efficacy of these transplantation treatments for Inflammatory Bowel
Disease. While some of these proposals may go beyond standard approvable boundaries and may
fail to pass the regulations stipulated by the Institutional Review Board, these suggested goals
and experiments can offer invaluable knowledge and insight that might not otherwise be attained
through proposals and experiments that pass review board guidelines.
This review proposes that both observational and experimental studies are necessary to
further examine the safety profile and effectiveness of FMT in IBD. In terms of observational
studies, this review proposes the establishment of two longitudinal studies that will follow two
specific cohorts. These suggested longitudinal studies will attempt to establish a wider scope for
genetic profiling the gut microbiomes of IBD populations that have previously received FMT
treatments and populations that have an elevated prospect of developing IBD in the future.
The first proposal is a lifetime longitudinal study that will follow all IBD patients,
worldwide, who have previously received FMT treatments. When possible, genomic sequencing
of donor samples (documenting both the microbial community and microbiome of the stool
samples) for each IBD patient should be kept on file as well. At regular time intervals (i.e.
biannually), participants of this study will be required to fill out a selfreported questionnaire that
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will assess their health conditions postFMT in order to determine if time has an effect on disease
symptom resolution (for IBD patients in which FMT was deemed unsuccessful in a prior study)
and/or symptom flare ups (for IBD patients in which FMT was deemed successful in studies).
This longitudinal study will also require that participants’ stool samples be metagenomically
analyzed (i.e. via Next Generation Sequencing techniques) at regular time intervals as well, in
order to determine the gut microbial compositions, species interactions, and gene products that
may influence disease symptom resolution and/or flareups (Koboldt et al., 2013). Genetically
analyzing the stool samples on a regular basis will also potentially allow researchers to make
important discoveries. For example, it might reveal that time is a necessary factor for a patient’s
gut microbiome to converge towards their donor’s; it will also help to elucidate if this
convergence over time allows for a higher rate of disease resolution. The proposal of this
longitudinal study is based on information gathered from a couple of studies. A study previously
suggested that the IBD patients who responded the most positively to FMT treatments tended to
have microbiota profiles that were similar to that of their donors (after a 12 week follow up
period), whereas the microbial diversity of nonresponders did not change over time (Rossen et
al., 2015b). Another study demonstrated that FMT induced a transient flareup of UC in a
patient, which had previously been dormant for 20 years, when used to treat the patient’s CDI
symptoms, indicating the potential for FMT treatments to exacerbate or revive IBD symptoms
postFMT (De Leon et al., 2013). This longitudinal study can help to confirm whether the
findings from these existing studies are valid, as well as contribute to elucidating the gut
microbiome that is most susceptible to IBD genesis and what aspects of that microbiome must be
restored in order for IBD eradication.
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The second longitudinal study will follow a different cohortpregnant women with IBD
and the child/children they give birth to during that pregnancy. The participants of this study
(mothers and children) would be required to give stool samples at regular intervals for
metagenomic analyzation as well. The children would also be required to fill out selfreported
questionnaires, either by themselves or by proxy, at regular time intervals that inquire about their
main diets and when their IBD symptoms started (when applicable). The main aim of this study
would be to examine the heritability of IBD and hopefully document the exact microbial shifts
that lead to the onset of IBD. A secondary goal of this study would be to investigate the role diet
has on changing one’s commensal gut microbiome and if these changes eventually give rise to
IBD. Existing literature that inspired the proposal of this study are those that document evidence
of IBD’s heritability and studies supporting the claim that diet has an effect on shaping one’s gut
microbiota (Cho et al., 2011 & Filippo et al., 2010). While it is understandable how these studies
might not be approved by a review board, as they warrant meticulous protocols from participants
and researchers, these proposed longitudinal studies have the potential to reveal valuable insight
on IBD’s pathogenesis that can lead to more streamlined and targeted approaches to microbial
restoration therapies that have the possibility of replacing traditional FMT procedures.
In addition to longitudinal studies, this review will also propose a series of experimental
studies that should be considered when examining the safety and efficacy of FMT in IBD. The
two primary goals of these experimental studies are to: (1) establish a standardized FMT protocol
specific to IBD, and (2) find IBD populations that are the most suited for FMT treatments. While
many studies reference and use existing FMT algorithms for CDI in IBD, it is important to create
a FMT protocol specific to IBD because IBD pathology differs greatly from the etiology of CDI.
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While existing FMT protocols for CDI are a good place to start from, IBD’s multifactorial
pathogenesis makes it so that it is not practical to solely rely on the CDI’s FMT methodologies
for IBD. For example, despite the variability in FMT procedural protocols for CDI, FMT still
demonstrates high resolution rates for CDI with little adverse side effects. However, procedural
variability for FMT in IBD does not exhibit the same high cure rates and low side effects that
CDI does, highlighting the importance of establishing a standard protocol tailored for IBD. A
standardized protocol for IBD is also a crucial and necessary step to normalizing and minimizing
the bias associated with FMT in IBD, which is a critical issue involving much of the existing
literature documenting FMT usage in IBD. The lack of procedural standardization makes it not
only extremely difficult to interpret and compare results across different studies, it is also a
potential reason why FMT exhibits relatively lower resolution rates with IBD; FMT protocols
regarding route of administration, fecal solution preparation, patient preparation, and donor
selection processes for IBD are all ill defined. Furthermore, because existing literature has also
shown that the efficacy of FMT treatments in IBD is highly variable, ranging from resolution
rates of 0% to 68% in some studies, it would seem as though only certain IBD populations may
benefit from FMT therapies (Rossen et al., 2015a). Overall, it is important to establish a standard
FMT procedure for IBD as well as find the subsets of IBD patients that are most suited to receive
FMT treatments.
In order to achieve the goal of protocol standardization, it is necessary to carry out
experiments that are aimed at elucidating which route of administration is better for specific IBD
populations in terms of efficacy. It is also important to determine which route of administration
is better because a previous study has mentioned that certain delivery routes may be more
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beneficial to particular groups of bacteria (Ianiro et al., 2014). A way to test which
administration route is better suited for certain IBD populations is a series of experiments
enrolling men and women, with IBD, of different age groups with varying states of health. For
example, one clinical trial should only admit patients with mildly active disease states who are
randomly assigned a method of delivery (i.e. oral, NJ/NG tube, enema, colonoscopy, etc). Some
controls for this experiment should be: diet (i.e. patients should eat a diet low in fat and animal
protein, but rich in fiber and plant polysaccharides as these foods have been associated with
microbial species richness and diversity in a previous study), disease state (only mildly active
IBD patients should be admitted to best demonstrate the effect of delivery route on disease
resolution), immunocompromisation (participants should be relatively healthy besides mild IBD
symptoms; BMI should be under 30), age (participants should be at least 16 years old to allow
better retention of larger fluid volumes for enemas), fecal solution preparation (i.e. 50 grams of
fresh fecal matter from anonymous donors suspended in 500 mL of saline, as these numbers
demonstrated higher cure rates for CDI), and bowel lavage procedures (none to minimize the
disruption of existing microflora) (Filippo et al., 2010 & Rohlke et al., 2012). This experiment
will help to establish a baseline for what route of delivery is most effective at resolving
symptoms for relatively healthy IBD patients. Further experiments can repeat this protocol with
different populations of IBD patients (i.e. infants under the age of 3, severely
immunocompromised patients, patients with refractory IBD, etc). Additional experiments can
also take into account which delivery method has the highest patient “buyin” and which route is
the easiest to administer. It should also be noted that previous studies examining the effect of
FMT in CDI have mentioned that a potential disadvantage of using colonoscopic procedures is
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the risk of colon perforation, so future researchers should also take this into consideration when
administering FMT via colonoscopy (Dodin et al., 2014). Previous clinical trials studying FMT
in CDI have also shown that fecal matter suspended in at least 500 mL of diluent tended to
exhibit higher resolution rates (Rohlke et al., 2012). However, this ideal volume might change
depending on the route of FMT delivery; future researchers should take time to investigate the
volume of diluent that is most effective for each method of administration.
Another method to achieving the goal of protocol standardization is figuring out what the
donor requirements should be for FMT used in treating Inflammatory Bowel Disease. For
example, in addition to the donor specifications used for FMT in CDI, stricter guidelines should
be implemented for IBD patients’ FMT donors as IBD patients are usually more
immunocompromised than CDI patients (due to the intake of antiinflammatory drugs). In light
of this, donors for IBD patients should always have their stools metagenomically analyzed to
detect for potential pathogens that may be likely to cause disease for IBD patients but not for
CDI patients. Metagenomically analyzing donors’ stool samples is also important because a
previous study has shown that donor species richness has an effect on transplantation success for
certain IBD patients (Vermeire et al., 2015). Additionally, genetic factors are an area of influence
for IBD patients while it is not for CDI patients. Due to these genetic influences on IBD
pathogenesis, an example of an experiment that should be executed should be one that tests this
hypothesis: anonymous donors have higher rates of resolution than genetically related donors. If
this first test proves to be true, a follow up test should be performed to test the hypothesis that:
genetically related donors exhibit higher rates of relapse after initial resolutions. If this second
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test also proves to be true then great caution should be taken when patients wish to use
genetically related donors for fecal microbiota transplantations.
In addition to determining which route of administration is most effective and what the
donor guidelines should be for FMT usage in IBD, it is also important to demonstrate which
methods of fecal matter preparation and administration exhibit the highest resolution rates for
IBD patients. An example of a first test that should be run is one that analyzes the hypothesis:
fresh fecal matter has higher rates of resolution than frozen fecal matter (as a previous study
indicated that using fresh fecal matter had higher cure rates than using frozen matter but the
results were not significant, probably due to its small sample size) (Cui et al., 2015a). Important
controls for this experiment would be: donor BMI, the amount of fecal matter used, the volume
of diluent used, and what type of diluent is used (i.e. saline, water, milk, yogurt, etc). If it is
demonstrated that using fresh fecal matter does indeed have a higher rate of resolution for IBD
patients, then an additional experiment should done to test the following hypothesis: fecal matter
purified by a machine (i.e. the GenFMTer) and then frozen demonstrates similar efficacy rates as
using fresh matter. If this too is demonstrated to be true, then using frozen stool samples may be
as effective as using fresh stool samples for IBD patients, which is important because using
frozens stool samples allows for immediate administration while fresh stool samples must be
prepared for a period of time before administration is possible. Other potential areas of
procedural standardization that should be further explored in order to determine the safety and
efficacy of FMT treatments for IBD patients are: establishing how many FMT treatments are
typically needed for disease resolution and determining if combination therapies (i.e. FMT
combined with steroid therapies) are effective (Cui et al., 2015c).
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Along with designing experiments aimed at standardizing FMT procedures for IBD
patients, another goal of the proposed experiments in this review is to find IBD populations that
are the most suited for FMT treatments. A method of achieving this particular goal is conducting
a series of experiments that test the efficacy of FMT treatments on a wide variety of IBD
patients (i.e. pediatric populations, adult populations, immunocompromised patients, steroid
dependent patients, refractory patients, newly diagnosed patients etc). An example of such an
experiment is a randomized control trial that only admits pediatric IBD populations under the age
of 3 (
as ages 35 is when an infant’s microbiota starts to converge to adultlike microbiota
compositions) in order to see if FMT treatments can induce higher resolution rates in this
population subset than a placebo counterpart can (i.e. a placebo using just saline) (
Rodríguez et
al., 2015
). Some controls of this experiment should be: the amount of stool infused (i.e. 50
grams of fresh stool), volume of diluent (i.e. 250 mL of saline, as 500 mL of saline may be too
much liquid for an infant to retain), the participant’s state of health (should be relatively healthy
with only mildly active disease symptoms), the method of administration (i.e. colonoscopy,
based on a previous experiment that demonstrated high efficacy in treating CDI with FMT for
two children under the age of 3), type of donor (i.e. anonymous donors only), and if a bowel
lavage procedure is used (It is recommended that no bowel lavage is used due to its invasive
nature and unproven efficacy in IBD symptom resolution) (Ritu et al., 2014). If this first
experiment fails to demonstrate the efficacy of FMT treatments on this IBD population
subgroup, it is recommended that the same control trial is repeated while changing one of the
controls listed above (i.e. delivery via a NJ/NG tube instead of a colonoscopy or using a higher
volume of saline if patients can tolerate it) to see if there are any changes in symptom resolution
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rates. Similar randomized control trials can be conducted across the different IBD subgroups in
order to better demonstrate which populations of IBD are the most suitable for FMT treatments.
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Conclusion.
All in all, the proposals of goals and studies listed in this review are not exhaustive of all
the concerns regarding safety and efficacy that must be addressed when determining if fecal
microbiota transplantations should be considered a therapeutic option in the treatment of
Inflammatory Bowel Disease. However, this review does demonstrate that there are still many
areas of research that need to be further explored and studied before truly determining if FMT
treatments are safe and effective therapies for IBD patients.
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Appendix.
Notable Abbreviations Used
CDI

Clostridium difficile 
Infection

IBD

Inflammatory Bowel Disease

FMT

Fecal Microbiota Transplantation

UC

Ulcerative Colitis

CD

Crohn’s Disease
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